Basket | Login | Register

 
 
 
 

Lithuania

2012: National Dementia Strategies (diagnosis, treatment and research)

Issues relating to medical treatment

The availability of medicines in general

Medicines in Lithuania are fully covered for children under 18, persons with group 1 disability and for hospital treatment. 50% of the price of medicines is covered for old-age pensioners, persons with group 2 disability and other persons entitled to a social insurance protection[1].

The Lithuanian system prescribes reimbursement levels for medicines for specific diseases on a special list for which reimbursement can be 50%, 80%, 90% or 100% depending on the disease.

Conditions surrounding the prescription and reimbursement of AD drugs

In Lithuania, only donepezil and memantine are part of the reimbursement system. People with an MMSE score between 20 and 0 can qualify for the reimbursement of donepezil. There are no restrictions in Lithuania for the reimbursement of these treatments for people living alone or in nursing homes.

Prescription and reimbursement

Donepezil

Rivastigmine

Galantamine

Memantine

Available

Yes

No

No

Yes

Reimbursed

Yes

N/A

N/A

Yes

Required examinations

MMSE

N/A

N/A

 

MMSE limits

20-0

N/A

N/A

 

Issues relating to research

Lithuania is not involved in the EU Joint Programme – Neurodegenerative Disease Research (JPND) but is an Associate member of the Joint Action “Alzheimer Cooperative Valuation in Europe (ALCOVE)”.

[1] European Commission (2011): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland: Comparative tables

 

 
 

Last Updated: Tuesday 14 May 2013

 

 
  • Acknowledgements

    The above information was published in the 2012 Dementia in Europe Yearbook as part of Alzheimer Europe's 2012 Work Plan which received funding from the European Union in the framework of the Health Programme. Alzheimer Europe gratefully acknowledges the support it has received from the Alzheimer Europe Foundation for the preparation and publication of its 2012 Yearbook.
  • European Union
 
 

Options